Fox Corp Class B vs GeneDx Holdings Corp — how do they compare? Fox Corp Class B trades at $50.96 (market cap $22.28B), while GeneDx Holdings Corp trades at $64.82 (market cap $1.96B). The key difference: Fox Corp Class B is far larger — about 11.4× GeneDx Holdings Corp's market cap, and Fox Corp Class B pays a 1.11% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| FOX | WGS | |
|---|---|---|
Market Cap | $22.28B | $1.96B |
Sector | Media | Technology |
52-Week High | $67.76 | $167.51 |
52-Week Low | $44.39 | $34.51 |
Enterprise Value | $26.25B | $1.96B |
Dividend Yield | 1.11% | — |
Signals from Pluang's Aura AI — not financial advice
FOX trades at $49.50, down 1.43% today, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamental performance with Q1 2026 EPS beating expectations at $1.32 versus $0.988, continuing a trend of earnings surprises. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. Analyst sentiment is mixed with 43% buy ratings but technical weakness persists near key support levels.
The outlook remains cautiously optimistic given FOX's consistent earnings beats and improved cash flow generation, though technical weakness and competitive pressures in media streaming present near-term challenges. The stock offers reasonable valuation with P/E of 13.26x, but investors should monitor advertising trends and Roku integration execution risks.
No Aura AI signal available yet.
Trailing returns across standard periods
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →